shutterstock_1873015870_alpha_tauri_3d_graphics
Alpha Tauri 3D Graphics / Shutterstock.com
23 August 2022FeaturesBiotechIne Vanderleyden

Microbial consortia and IP in Europe

Our body hosts trillions of microorganisms that live symbiotically on and within the human body. This ‘microbiome’ is essential to our health and microbial imbalance or dysbiosis increases the susceptibility to many diseases, including inflammatory bowel disease (IBD), liver disease, atherosclerosis, and other severe pathologies. Given its central role in health and disease, the microbiome has become a prominent therapeutic target.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
Biotech
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
Biotech
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.